RonaldGStollerMD

PubMed

• A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer...
  Monica K Malhotra, Shalu Pahuja, Brian F Kiesel, Leonard J Appleman, Fei Ding, Yan Lin, Hussein A Tawbi, Ronald G Stoller, James J Lee, Chandra P Belani, Alice P Chen,...> ;Breast Cancer Research and Treatment. 2023 Apr 1
• 5 citations
  A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovari...
  Julia Manzo, Shannon Puhalla, Shalu Pahuja, Fei Ding, Yan Lin, Leonard Appleman, Hussein Tawbi, Ronald Stoller, James J Lee, Brenda Diergaarde, Brian F Kiesel, Jing Yu...> ;Cancer Chemotherapy and Pharmacology. 2022 May 1
• 1 citations
  Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors
  William F. Maguire, John C. Schmitz, Jonas Scemama, Ken Czambel, Yan Lin, Anthony Green, Shaoyu Wu, Huang Lin, Shannon Puhalla, John C. Rhee, Ronald G. Stoller, Hussei...> ;Cancer Chemotherapy and Pharmacology. 2021 Jun 23
• 27 citations
  Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies
  Leonard Joseph Appleman, Jan H. Beumer, Yixing Jiang, Yan Lin, Fei Ding, Shannon Puhalla, Leigh Swartz, Taofeek K. Owonikoko, R. Donald Harvey, Ronald G. Stoller, Dani...> ;Cancer Chemotherapy and Pharmacology. 2019 Dec 1
• 30 citations
  Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or l...
  Kimmen Quan, Philip A. Sutera, Karen M. Xu, Mark E. Bernard, Steven A. Burton, Rodney E. Wegner, Herbert J. Zeh, Nathan Bahary, Ronald G. Stoller, Dwight E. Heron> ;Practical Radiation Oncology. 2017 Oct 7
• 11 citations
  Phase I study of veliparib in combination with gemcitabine.
  Ronald G. Stoller, John C. Schmitz, Fei Ding, Shannon Puhalla, Chandra P. Belani, Leonard Joseph Appleman, Yan Lin, Yixing Jiang, Salah Almokadem, Daniel P. Petro, Jul...> ;Cancer Chemotherapy and Pharmacology. 2017 Aug 2
• 128 citations
  Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastri...
  Manish A. Shah, Yelena Y. Janjigian, Ronald G. Stoller, Stephen Shibata, Margaret Kemeny, Smitha S. Krishnamurthi, Yungpo Bernard Su, Allyson J. Ocean, M. Capanu, Bhoo...> ;Journal of Clinical Oncology. 2015 Nov 20
• 171 citations
  A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors
  Jordi Rodon, Hussein Tawbi, Anne L. Thomas, Ronald G. Stoller, Christian P. Turtschi, José Baselga, John Sarantopoulos, Devalingam Mahalingam, Yaping Shou, Melissa A. ...> ;Clinical Cancer Research. 2014 Apr 1
• Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers.
  Tawbi, H.,Christner, S. M.,Lin, Y.,Johnson, M.,Mowrey, E. T.,Cherrin, C.,Chu, E.,Lee, J. J.,Puhalla, S.,Stoller, R.,Appleman, L. R.,Miller, B. M.,Beumer, J. H.> ;Cancer Chemother. Pharmacol.. 2013 Oct 31
• Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers.
  Tawbi, H. A.,Tran, A. L.,Christner, S. M.,Lin, Y.,Johnson, M.,Mowrey, E.,Appleman, L. R.,Stoller, R.,Miller, B. M.,Egorin, M. J.,Beumer, J. H.> ;Cancer Chemother. Pharmacol.. 2013 Sep 14
• 137 citations
  Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer
  Brian A. Boone, Jennifer Steve, Alyssa M. Krasinskas, Amer H. Zureikat, Barry C. Lembersky, Michael K. Gibson, Ronald G. Stoller, Herbert J. Zeh, Nathan Bahary> ;Journal of Surgical Oncology. 2013 Sep 1
• 7 citations
  Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients
  Huali Wu, Ramesh K. Ramanathan, Beth A. Zamboni, Sandra Strychor, Suresh S. Ramalingam, Robert P. Edwards, David M. Friedland, Ronald G. Stoller, Chandra P. Belani, La...> ;International Journal of Nanomedicine. 2012 Oct 19
• 17 citations
  Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies
  Athanassios Argiris, T. M. Feinstein, Lin Wang, Tianbing Yang, Shruti Agrawal, Leonard Joseph Appleman, Ronald G. Stoller, Jennifer R. Grandis, Ann Marie Egloff> ;Investigational New Drugs. 2012 Aug 1
• 30 citations
  A phase I and pharmacokinetic study of oral 3-aminopyridine-2- carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: A...
  Joseph Chao, Timothy W. Synold, Robert J. Morgan, Charles A. Kunos, Jeff Longmate, Heinz-Josef Lenz, Dean Lim, Stephen Shibata, Vincent Chung, Ronald G. Stoller, Chand...> ;Cancer Chemotherapy and Pharmacology. 2012 Mar 1
• 13 citations
  Phase II Study of Irinotecan and Cetuximab Given Every 2 Weeks as Second-Line Therapy for Advanced Colorectal Cancer
  Benedito A. Carneiro, Ramesh K. Ramanathan, Smitha S. Krishnamurthi, Barry C. Lembersky, Ronald G. Stoller, Stewart L. Lancaster, Theodore L. Crandall, Amy Schmotzer, ...> ;Clinical Colorectal Cancer. 2012 Mar 1
• 25 citations
  Population Pharmacokinetics of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies
  Huali Wu, Ramesh K. Ramanathan, Beth A. Zamboni, Sandra Strychor, Suresh Ramalingam, Robert P. Edwards, David M. Friedland, Ronald G. Stoller, Chandra P. Belani, Laure...> ;Journal of Clinical Pharmacology. 2012 Feb 1
• 36 citations
  Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors
  William C. Zamboni, Lauren J. Maruca, Sandra Strychor, Beth A. Zamboni, Suresh Ramalingam, Robert P. Edwards, J. K. Kim, Yung Jue Bang, H-Y Lee, David M. Friedland, Ro...> ;Journal of Liposome Research. 2011 May 18
• 9 citations
  The spectrum of coincident entities with small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) diagnosed by cytology.
  Hannah A. Kastenbaum, Walid E. Khalbuss, Raymond E. Felgar, Ronald G. Stoller, Sara E. Monaco> ;Cytojournal. 2010 Jan 1
• 32 citations
  Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
  William C. Zamboni, S. Strychor, Lauren J. Maruca, Sakkaraiappan Ramalingam, Beth A. Zamboni, Huali Wu, David M. Friedland, Robert P. Edwards, Ronald G. Stoller, Chand...> ;Clinical Pharmacology and Therapeutics. 2009 Nov 1
• Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors.
  Wu H, Ramanathan RK, Srychor S, Zamboni BA, Ramalingam S, Edwards RP, Friedland DM, Stoller RG, Belani CP, Zamboni WC> ;J. Clin. Oncol.. 2009-05-20
• Phase I and pharmacokinetic (PK) study of dasatinib (D) and cetuximab (C) in patients (pts) with advanced solid malignancies.
  Feinstein TM, Agrawal S, Stoller RG, Egorin MJ, Argiris A> ;J. Clin. Oncol.. 2009-05-20
• 43 citations
  Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 in Patients with Advanced Malignancies
  William C. Zamboni, Suresh Ramalingam, David M. Friedland, Robert P. Edwards, Ronald G. Stoller, Sandra Strychor, Lauren J. Maruca, Beth A. Zamboni, Chandra P. Belani,...> ;Clinical Cancer Research. 2009 Feb 15
• 49 citations
  A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
  Suresh S. Ramalingam, Merrill J. Egorin, Ramesh K. Ramanathan, Scot C. Remick, Rachel P. Sikorski, Theodore F. Lagattuta, Gurkamal Chatta, David M. Friedland, Ronald G...> ;Clinical Cancer Research. 2008 Jun 1
• Phase I trial of cetuximab (C) and dasatinib (D) in patients (pts) with advanced solid malignancies.
  Esteve FR, Stoller RG, Josephson A, Grandis JR, Egorin MJ, Argiris AE> ;J. Clin. Oncol.. 2008-05-20
• Phase II study of RAD001 (Everolimus) in previously treated small cell lung cancer (SCLC).
  Owonikoko TK, Stoller RG, Petro D, Flaugh R, Hershberger PA, Belani CP, Argiris AE> ;J. Clin. Oncol.. 2008-05-20
• Join now to see all